INFLUENCE OF LOCAL APPLICATION OF POLYOXIDONIUM ON SYMPTOMS AND COURSE OF ACUTE RESPIRATORY VIRAL INFECTION IN CHILDREN: RESULTS OF MULTICENTER DOUBLE-BLIND PLACEBO CONTROLLED STUDY
- Authors: Garashchenko T.I.1,2, Karneeva O.V.1,2, Tarasova G.D.2, Kim I.A.1,2, Hanferian R.A.2,3
-
Affiliations:
- Pirogov Russian National Research Medical University
- Scientific and Clinical Center of Otorhinolaryngology
- People’s Friendship University of Russia
- Issue: Vol 22, No 3 (2020)
- Pages: 80-86
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/95247
- DOI: https://doi.org/10.26442/20751753.2020.3.200091
- ID: 95247
Cite item
Full Text
Abstract
Aim. To confirm advantages of Polyoxidonium® local application therapeutic effect in comparison with placebo when being used as a part of complex therapy in children aged 1 to 12 years diagnosed with acute respiratory viral infection (ARVI). Materials and methods. The study included 155 children aged 1 to 12 years diagnosed with ARVI. The study group included 76 children in whom complex therapy included Polyoxidonium® and comparison group included 79 children who received placebo as a part of complex therapy. The study outcome measures evaluating therapy effectiveness included intoxication symptoms, nasal mucosa inflammation dynamics, total sum of the symptoms points at the 3rd, 5th, and 8th days of treatment, and the duration of fever. Results. According to study results the advantage of Polyoxidonium® use in comparison with placebo in complex treatment of children aged 1 to 12 years diagnosed with ARVI was established. Inclusion of Polyoxidonium in complex ARVI treatment in children allows to provide better control of intoxication symptoms to decrease severity of symptoms such as “nasal discharge” and “nasal blockage” by the 5th day of treatment, to double the amount of patients without the “nasal discharge” symptom by the 3rd and 5th days of treatment, and to decrease the severity of infection inflammatory process. Conclusion. Local application of Polyoxidonium® in complex treatment of ARVI in children aged 1 to 12 years showed clinical effectiveness and safety.
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana I. Garashchenko
Pirogov Russian National Research Medical University; Scientific and Clinical Center of Otorhinolaryngology; Pirogov Russian National Research Medical University
Email: 9040100@mail.ru
д-р мед. наук, проф., ученый секретарь ФГБУ НКЦО, проф. каф. оториноларингологии
Olga V. Karneeva
Pirogov Russian National Research Medical University; Scientific and Clinical Center of Otorhinolaryngology; Pirogov Russian National Research Medical Universityд-р мед. наук, проф. каф. оториноларингологии
Galina D. Tarasova
Scientific and Clinical Center of Otorhinolaryngology; Scientific and Clinical Center of Otorhinolaryngologyд-р мед. наук, гл. науч. сотр.
Irina A. Kim
Pirogov Russian National Research Medical University; Scientific and Clinical Center of Otorhinolaryngology; Pirogov Russian National Research Medical Universityд-р мед. наук, проф. каф. оториноларингологии
Roman A. Hanferian
Scientific and Clinical Center of Otorhinolaryngology; People’s Friendship University of Russia; Scientific and Clinical Center of Otorhinolaryngologyд-р мед. наук, проф. каф. иммунологии и аллергологии
References
- Караулов А.В., Горелов А.В. Применение азоксимера бромида в терапии инфекционно-воспалительных заболеваний органов дыхания у детей: мета-анализ контролируемых клинических исследований. Журн. инфектологии. 2019; 11 (4): 31-41. @@Karaulov A.V., Gorelov A.V. Primenenie azoksimera bromida v terapii infektsionno-vospalitel'nykh zabolevanii organov dykhaniia u detei: meta-analiz kontroliruemykh klinicheskikh issledovanii. Zhurn. infektologii. 2019; 11 (4): 31-41 (in Russian).
- Богомильский М.Р., Чистякова В.Р. Детская оториноларингология. М.: ГЭОТАР-Медиа, 2001. @@Bogomilsky M.R., Chistyakova V.R. Children's otorhinolaryngology. Moscow: GEOTAR-Media, 2001 (in Russian).
- Андрюков Б.Г., Сомова Л.М., Дробот Е.И., Матосова Е.В. Антимикробные стратегии нейтрофилов при инфекционной патологии. Клин. лаб. диагностика. 2016; 61 (12). @@Andriukov B.G., Somova L.M., Drobot E.I., Matosova E.V. Antimikrobnye strategii neitrofilov pri infektsionnoi patologii. Klin. lab. diagnostika (Russian clinical laboratory diagnostics). 2016; 61 (12) (in Russian).
- Val S, Poley M, Brown K et al. Proteomic Characterization of Middle Ear Fluid Confirms Neutrophil Extracellular Traps as a Predominant Innate Immune Response in Chronic Otitis Media. PLoS ONE 2016; 11 (4).
- Novel concepts in nontypeable Haemophilus influenzae biofilm formation. FEMS Microbiol Lett 2013; 346 (2): 81-9.
- Toussaint M et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med 2017; 23 (6): 681-91.
- Вавилова В.П., Вавилов А.М., Черкаева А.Х. Возможности современной терапии острых респираторных вирусных инфекций у детей. Педиатрия. Consilium Medicum. 2015; 3: 76-81. ИНФОРМАЦИЯ ОБ АВТОРАХ / INFORMATION ABOUT THE AUTHORS @@Vavilova V.P., Vavilov A.M., Cherkaeva A.Kh. Possibilities of modern therapy for acute respiratory viral infections in children. Pediatrics. Consilium Medicum. 2015; 3: 76-81 (in Russian).
- Пинегин Б.В. и др. Влияние азоксимера бромида на формирование внеклеточных нейтрофильных ловушек. РМЖ. 2019; 1 (II): 42-6. @@Pinegin B.V. et al. Vliianie azoksimera bromida na formirovanie vnekletochnykh neitrofil'nykh lovushek. RMZh. 2019; 1 (II): 42-6 (in Russian).
- Исаева Е.И и др. Изучение противовирусной активности Полиоксидония на экспериментальной модели in vitro. Журн. инфектологии. 2019 (Прил. 1). @@Isaeva E.I et al. Izuchenie protivovirusnoi aktivnosti Polioksidoniia na eksperimental'noi modeli in vitro. Zhurn. infektologii. 2019 (Pril. 1) (in Russian).
- Харит С.М., Галустян А.Н. Азоксимера бромид - безопасный и эффективный препарат при лечении острых респираторных инфекций верхних дыхательных путей у детей: обзор результатов двойных слепых плацебо-контролируемых рандомизированных клинических исследований II и III фазы. Педиатрия. Consilium Medicum. 2017; 2: 55-61.
Supplementary files
